PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects
Conclusion: Maximal PED height continuously decreased over time. Switching the intravitreal anti–vascular endothelial growth factor medication from ranibizumab to aflibercept had a significantly stronger short-term effect on PED height reduction, without changes in visual acuity. (Source: RETINA)
Source: RETINA - April 26, 2016 Category: Opthalmology Tags: Original Study Source Type: research

The short ‐term effects of aflibercept on the size of choroidal neovascularization lesion in treatment‐resistant neovascular age‐related macular degeneration as determined by spectral‐domain optical coherence tomography
Background and ObjectivesTo evaluate the changes in the size of choroidal neovascularization (CNV) lesion using spectral domain‐optical coherence tomography (SD‐OCT) in patients with treatment‐resistant neovascular age‐related macular degeneration (AMD) who were switched from ranibizumab to aflibercept. Materials and MethodsIn this prospective case‐series, 33 eyes of 30 patients with treatment‐resistant neovascular AMD were included. Treatment‐resistant neovascular AMD was defined as choriodal neovascularization secondary to AMD determined by subretinal fluid and/or intraretinal fluid/cysts after more than 6 ...
Source: Lasers in Surgery and Medicine - April 25, 2016 Category: Laser Surgery Authors: Kaveh Abri Aghdam, Florian Seidensticker, Amelie Pielen, Carsten Framme, Bernd Junker Tags: Clinical Reports Source Type: research

Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration
Conclusion: Repeated intravitreal injections of an anti-VEGF drug for AMD may lead to morphological and functional changes in large arteries.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - April 15, 2016 Category: Opthalmology Source Type: research

The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting
C Alagoz, R Garip, Z Alkin, I Perente, A T Yazici & M Taskapili (Source: Eye)
Source: Eye - April 15, 2016 Category: Opthalmology Authors: A Ozkaya Source Type: research

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME) in the Greek setting. (Source: Cost Effectiveness and Resource Allocation)
Source: Cost Effectiveness and Resource Allocation - April 14, 2016 Category: Health Management Authors: Georgia Kourlaba, John Relakis, Ronan Mahon, Maria Kalogeropoulou, Georgia Pantelopoulou, Olga Kousidou and Nikos Maniadakis Source Type: research

Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab.
CONCLUSIONS: These findings suggest that the aqueous flare is associated with inflammatory factors/cytokines, and that the change of the aqueous flare value may influence the long-term prognosis in patients with BRVO receiving IRI therapy for macular oedema. PMID: 27073207 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - April 12, 2016 Category: Opthalmology Authors: Noma H, Mimura T, Yasuda K, Shimura M Tags: Br J Ophthalmol Source Type: research

Changes in intraocular pressure in study and fellow eyes in the IVAN trial.
Abstract PURPOSE: To describe changes in intraocular pressure (IOP) in the 'alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)' trial (registered as ISRCTN92166560). DESIGN: Randomised controlled clinical trial with factorial design. PARTICIPANTS: Patients (n=610) with treatment naïve neovascular age-related macular degeneration were enrolled and randomly assigned to receive either ranibizumab or bevacizumab and to two regimens, namely monthly (continuous) or as needed (discontinuous) treatment. METHODS: At monthly visits, IOP was measured preinjection in ...
Source: The British Journal of Ophthalmology - April 12, 2016 Category: Opthalmology Authors: Foss AJ, Scott LJ, Rogers CA, Reeves BC, Ghanchi F, Gibson J, Chakravarthy U, IVAN study group Tags: Br J Ophthalmol Source Type: research

Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
CONCLUSIONS: Ranibizumab and aflibercept exert similar effects on VEGF expression and secretion, leading to establishing an antiangiogenic environment. Increased VEGF-A expression observed in RPE cells treated with these drugs suggests a compensatory response of the cells to the lack of VEGF-A. PMID: 27079208 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 12, 2016 Category: Opthalmology Authors: Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M Tags: Eur J Ophthalmol Source Type: research

Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network
Purpose of review: Diabetic retinopathy and diabetic macular edema (DME) are common eye diseases leading to vision loss. The Diabetic Retinopathy Clinical Research Network (DRCRnet), a collaboration of private and academic practices supported by the National Eye Institute and the National Institute of Diabetes, Digestive and Kidney Diseases has studied diabetic eye disease for 13 years. This review will discuss the network's findings over the last year, when some of its most important contributions were reported. Recent findings: The DRCRnet reported intravitreal bevacizumab, ranibizumab and aflibercept all improve visual...
Source: Current Opinion in Ophthalmology - April 8, 2016 Category: Opthalmology Tags: RETINAL, VITREOUS AND MACULAR DISORDERS: Edited by Brandon G. Busbee and John W. Kitchens Source Type: research

Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases
ópez, G McGowan, E Chapman & D Yorston (Source: Eye)
Source: Eye - April 8, 2016 Category: Opthalmology Authors: J J González-López Source Type: research

Aflibercept vs. Ranibizumab: cost‐effectiveness of treatment for wet age‐related macular degeneration in Sweden
Abstract PurposeMonthly dosing with ranibizumab (RBZ) is needed to achieve maximal visual gains in patients with neovascular (‘wet’) age‐related macular degeneration (wAMD). In Sweden, dosing is performed as needed (RBZ PRN), resulting in suboptimal efficacy. Intravitreal aflibercept (IVT‐AFL) every 2 months after three initial monthly doses was clinically equivalent to RBZ monthly dosing (RBZ q4) in wAMD clinical trials. We assessed the cost‐effectiveness of IVT‐AFL versus RBZ q4 and RBZ PRN in Sweden. MethodsA Markov model compared IVT‐AFL to RBZ q4 or RBZ PRN over 2 years. Health states w...
Source: Acta Ophthalmologica - April 7, 2016 Category: Opthalmology Authors: Hemangi R. Panchmatia, Karen M. Clements, Erin Hulbert, Marianne Eriksson, Kim Wittrup‐Jensen, Jonas Nilsson, Milton C. Weinstein Tags: Original Article Source Type: research

Aflibercept vs. Ranibizumab: cost ‐effectiveness of treatment for wet age‐related macular degeneration in Sweden
Abstract PurposeMonthly dosing with ranibizumab (RBZ) is needed to achieve maximal visual gains in patients with neovascular (‘wet’) age‐related macular degeneration (wAMD). In Sweden, dosing is performed as needed (RBZ PRN), resulting in suboptimal efficacy. Intravitreal aflibercept (IVT‐AFL) every 2 months after three initial monthly doses was clinically equivalent to RBZ monthly dosing (RBZ q4) in wAMD clinical trials. We assessed the cost‐effectiveness of IVT‐AFL versus RBZ q4 and RBZ PRN in Sweden. MethodsA Markov model compared IVT‐AFL to RBZ q4 or RBZ PRN over 2 years. Health states w...
Source: Acta Ophthalmologica - April 7, 2016 Category: Opthalmology Authors: Hemangi R. Panchmatia, Karen M. Clements, Erin Hulbert, Marianne Eriksson, Kim Wittrup ‐Jensen, Jonas Nilsson, Milton C. Weinstein Tags: Original Article Source Type: research

A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept.
Authors: Seguin-Greenstein S, Lightman S, Tomkins-Netzer O Abstract With the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze all available evidence of visual and anatomical outcomes of eyes with resistant neovascular AMD switched to aflibercept at six months. Data from seven retrospective and prospective studies looking at change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) were included. Weigh...
Source: Journal of Ophthalmology - April 6, 2016 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Long-term resolution of blinding polypoidal choroidal vasculopathy with recurrent bilateral central involvement by low-dose oral eplerenone treatment
Alexander Arthur Bialasiewicz, Mahmoud Abdelhamid, Radha Shenoy, Manish BarmanMiddle East African Journal of Ophthalmology 2016 23(2):225-228A 55-year-old male presented with serous retinal detachment over 3 months in his right eye. His left eye was blind due to retinal pigment epithelium detachment since 1997 with atrophy of the neurosensory retina. Fluorescein angiography had previously shown bilateral polypoidal choroidal vasculopathy (PCV). Optical coherence tomography (OCT) confirmed PCV with central involvement. The patient underwent intravitreal injections of 6x Lucentis, 4x Avastin and one injection of aflibercept....
Source: Middle East African Journal of Ophthalmology - April 5, 2016 Category: Opthalmology Authors: Alexander Arthur BialasiewiczMahmoud AbdelhamidRadha ShenoyManish Barman Source Type: research

Anti-vascular endothelial growth factor treatment for proliferative macular telangiectasia type 2
Zeynep Alkin, Ihsan Yilmaz, Abdullah Ozkaya, Ahmet Taylan YaziciMiddle East African Journal of Ophthalmology 2016 23(2):222-224Idiopathic macular telangiectasia type 2 (IMT 2), is the most common type of a heterogeneous group of disorders, characterized by telangiectatic alterations of the juxtafoveolar capillary network. Vision loss is due to retinal atrophy and subretinal neovascularization (SRN). Here, we report the outcomes of intravitreal anti-vascular endothelial growth factor injections, bevacizumab or ranibizumab, in four cases with proliferative IMT 2. Baseline best corrected visual acuity (VA) ranged from 20/50 t...
Source: Middle East African Journal of Ophthalmology - April 5, 2016 Category: Opthalmology Authors: Zeynep AlkinIhsan YilmazAbdullah OzkayaAhmet Taylan Yazici Source Type: research

Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion
Abstract To assess the effect of intravitreal dexamethasone implant (Ozurdex) for the treatment of macular edema secondary to retinal vein occlusion (RVO) resistant to repeated intravitreal ranibizumab injection. Retrospective review of 11 patients (11 eyes) with ranibizumab-resistant macular edema secondary to RVO. Macular edema was considered refractory to ranibizumab if no change of the pattern of macular fluid on optical coherence tomography and no change of best-corrected visual acuity (BCVA) was observed after at least three consecutive monthly injections, excluding the loading dose. A single Ozurdex injecti...
Source: International Ophthalmology - April 4, 2016 Category: Opthalmology Source Type: research

Prefilled syringes for intravitreal injection reduce preparation time.
Authors: Subhi Y, Kjer B, Munch IC Abstract INTRODUCTION: The demand for intravitreal therapy has increased dramatically with the introduction of vascular endo-thelial growth factor inhibitors. Improved utilisation of existing resources is crucial to meeting the increased future demand. We investigated time spent preparing intravitreal injection treatment using either prefilled syringes or vials in routine clinical practice. METHODS: We video-recorded preparations of intravitreal injections (n = 172) for each preparation type (ranibizumab prefilled syringe (n = 56), ranibizumab vial (n = 56) and aflibercept via...
Source: Danish Medical Journal - April 2, 2016 Category: Journals (General) Tags: Dan Med J Source Type: research

Optical Coherence Tomography Angiography Of Pathological Myopia Sourced and Idiopathic Choroidal Neovascularization With Follow-Up
Abstract: To observe optical coherence tomography angiography (OCTA) images during follow-up of choroidal neovascularization (CNV) caused by pathological myopia (PM) or idiopathy and discuss OCTA's clinical applications Patients with CNV caused by PM or idiopathic CNV (ICNV) were recruited prospectively from the Department of Ophthalmology, West China Hospital from March 2015 to June 2015. Intravitreal injections of Ranibizumab were conducted on all patients and repeated treatments were performed based on examinations of follow-up. Patients received OCTA the first week after injection, together with measurements of best-c...
Source: Medicine - April 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Error in Table
This article was corrected online. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - April 1, 2016 Category: Opthalmology Source Type: research

Vascular Endothelial Growth Factor and Diabetic Macular Edema
Diabetes mellitus is a major global health epidemic, and diabetic macular edema (DME) is the leading cause of vision loss in this population. Macular focal and/or grid laser photocoagulation applied to microaneurysms and thickened retina had long been primary therapy for DME. Chronically elevated serum glucose is known to cause breakdown in the inner and outer retinal blood barrier resulting in up-regulation of vascular endothelial growth factor (VEGF). Intravitreal anti-VEGF agents, including ranibizumab, bevacizumab, and aflibercept, have been shown in randomized clinical trials to be superior to macular laser for the tr...
Source: Survey of Ophthalmology - April 1, 2016 Category: Opthalmology Authors: David R. Lally, Chirag P. Shah, Jeffrey S. Heier Tags: Major review Source Type: research

Real-world utilization of ranibizumab in wet age-related macular degeneration patients from Canada.
PMID: 27085258 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - April 1, 2016 Category: Opthalmology Authors: Devenyi R, Maberley D, Sheidow TG, Tourville E, Brunck L, Berger AR Tags: Can J Ophthalmol Source Type: research

Alterations in intraocular cytokine levels following intravitreal ranibizumab.
CONCLUSIONS: The changes in cytokine levels after IVR mirror the changes seen after IVB. Further studies are warranted in order to determine if there are any differences between IVB and IVR in this regard. OBJECTIF: Nos travaux antérieurs ont montré que, suite à l'administration de bevacizumab intravitréen (BIV), on constate une diminution des niveaux de FCEA-A et du facteur de croissance placentaire (PlGF), et une augmentation des niveaux d'IL-8 et de TGF-β2. Nous ne savons pas encore si des changements similaires se produisent suite à l'administration de ranibizumab intravitr&...
Source: Canadian Journal of Ophthalmology - April 1, 2016 Category: Opthalmology Authors: Forooghian F, Kertes PJ, Eng KT, Albiani DA, Kirker AW, Merkur AB, Fallah N, Cao S, Cui J, Or C, Matsubara JA Tags: Can J Ophthalmol Source Type: research

The short‐term effects of aflibercept on the size of choroidal neovascularization lesion in treatment‐resistant neovascular age‐related macular degeneration as determined by spectral‐domain optical coherence tomography
Background and ObjectivesTo evaluate the changes in the size of choroidal neovascularization (CNV) lesion using spectral domain‐optical coherence tomography (SD‐OCT) in patients with treatment‐resistant neovascular age‐related macular degeneration (AMD) who were switched from ranibizumab to aflibercept. Materials and MethodsIn this prospective case‐series, 33 eyes of 30 patients with treatment‐resistant neovascular AMD were included. Treatment‐resistant neovascular AMD was defined as choriodal neovascularization secondary to AMD determined by subretinal fluid and/or intraretinal fluid/cysts after more than 6 ...
Source: Lasers in Surgery and Medicine - April 1, 2016 Category: Laser Surgery Authors: Kaveh Abri Aghdam, Florian Seidensticker, Amelie Pielen, Carsten Framme, Bernd Junker Tags: Clinical Reports Source Type: research

Vascular endothelial growth factor and diabetic macular edema
Diabetes mellitus is a major global health epidemic, and diabetic macular edema is the leading cause of vision loss in this population. Macular focal and/or grid laser photocoagulation applied to microaneurysms and thickened retina had long been primary therapy for diabetic macular edema. Chronically elevated serum glucose is known to cause breakdown in the inner and outer retinal blood barrier resulting in upregulation of vascular endothelial growth factor (VEGF). Intravitreal anti –vascular endothelial growth factor agents, including ranibizumab, bevacizumab, and aflibercept, have been shown in randomized clinical ...
Source: Survey of Ophthalmology - April 1, 2016 Category: Opthalmology Authors: David R. Lally, Chirag P. Shah, Jeffrey S. Heier Tags: Major review Source Type: research

Is There Any Difference between Ranibizumab and Aflibercept Injections in Terms of Inflammation Measured with Anterior Chamber Flare Levels in Age-Related Macular Degeneration Patients: A Comparative Study
Conclusion: No significant short-term intraocular inflammation was noted in the eyes receiving aflibercept or ranibizumab for the treatment of neovascular AMD. Although aflibercept has more immunogenic properties than ranibizumab, such as having an extra Fc portion and being a larger molecule, it is likely that its more potent anti-inflammatory effects prevent it from inducing inflammation.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - March 30, 2016 Category: Opthalmology Source Type: research

Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy
Conclusion: A low number of intravitreal aflibercept injections reversed the preswitching trend toward losing vision and produced stable visual acuity and morphological improvements for up to 12 months in patients with neovascular age-related macular degeneration, not responding to ranibizumab. (Source: RETINA)
Source: RETINA - March 30, 2016 Category: Opthalmology Tags: Original Study Source Type: research

Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion
To compare the 6-month efficacy and safety profile of an individualized stabilization criteria–driven pro re nata (PRN) regimen of ranibizumab 0.5 mg with or without laser versus laser alone in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). (Source: Ophthalmology)
Source: Ophthalmology - March 30, 2016 Category: Opthalmology Authors: Ramin Tadayoni, Sebastian M. Waldstein, Francesco Boscia, Heinrich Gerding, Ian Pearce, Siegfried Priglinger, Andreas Wenzel, Elizabeth Barnes, Margarita Gekkieva, Stefan Pilz, Jordi Monés, BRIGHTER study group Source Type: research

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.
Abstract BACKGROUND/AIMS: To identify predictive markers for the outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD). METHODS: AURA was a retrospective, observational, multicentre study that monitored the 2-year outcomes following intravitreal ranibizumab treatment in patients with nAMD. Using stepwise regression analysis, we evaluated the association between visual acuity outcomes, baseline characteristics and resource utilisation in order to determine which variables are significantly linked to outcomes in AURA. We also examined the relationshi...
Source: The British Journal of Ophthalmology - March 30, 2016 Category: Opthalmology Authors: Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S Tags: Br J Ophthalmol Source Type: research

UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections.
CONCLUSIONS: This study provides times to retreatment in eyes with nAMD that have been treatment-free for intervals of 3-12 months and demonstrates the likelihood of repeat therapy within the next year, even after a TFI of 12 months. These outcomes can help plan appropriate follow-up intervals for patients who have been treatment-free for intervals of up to 12 months. PMID: 27030276 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - March 30, 2016 Category: Opthalmology Authors: Madhusudhana KC, Lee AY, Keane PA, Chakravarthy U, Johnston RL, Egan CA, Sim D, Zarranz-Ventura J, Tufail A, McKibbin M, UK AMD EMR Study Group Tags: Br J Ophthalmol Source Type: research

Morphologic Changes in Patient with Drusen and Drusenoid Pigment Epithelial Detachment after Intravitreal Ranibizumab for Choroidal Neovascular Membrane : A Case Report.
Authors: Kim S, Oh J, Kim K Abstract The authors present a case of morphologic changes of drusen and drusenoid pigment epithelial detachment (DPED) after treating choroidal neovascularization (CNV) using ranibizumab in age-related macular degeneration (AMD). A 71-year-old woman has noticed mild visual acuity deterioration in the right eye for several months. She was presented with some drusen and DPED associated with CNV. This patient was given intravitreal injection of 0.5 mg of ranibizumab five times at monthly intervals for treating CNV. DPED in the temporal and drusen in the superior to macula were diminished, ...
Source: Open Ophthalmology Journal - March 26, 2016 Category: Opthalmology Tags: Open Ophthalmol J Source Type: research

The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a “one size fits all” to an “individualised”... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - March 24, 2016 Category: Opthalmology Authors: Jennifer J. Arnold, Caroline M. Markey, Nicol P. Kurstjens and Robyn H. Guymer Source Type: research

Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age‐related macular degeneration: a comparative 12 Month study
Abstract PurposeTo compare outcomes in patients with treatment‐naïve neovascular age‐related macular degeneration (nAMD) receiving ranibizumab treat and extend (TE) with those receiving ranibizumab pro re nata (PRN) in a clinical setting. MethodsDuring this 12‐month retrospective, consecutive, comparative case series, patients received ranibizumab 0.5 mg according to a TE or PRN regimen. Monthly optical coherence tomography (OCT) evaluation was performed during the PRN regimen; retreatment criteria included recurrence of intra‐/subretinal fluid, or haemorrhages. During the TE regimen, initial treatment wi...
Source: Acta Ophthalmologica - March 24, 2016 Category: Opthalmology Authors: Katja Hatz, Christian Prünte Tags: Case Series Source Type: research

Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - March 24, 2016 Category: Opthalmology Authors: Qianyi Lu, Chen Zou, Hui Cao, Minjie Zhao, Siqing Yu, Qinghua Qiu, Xun Xu, Zhi Zheng Tags: Letter to the Editor Source Type: research

Distinct responsiveness to intravitreal ranibizumab therapy in polypoidal choroidal vasculopathy with single or multiple polyps
To understand the prognosis of polypoidal choroidal vasculopathy (PCV) by evaluating the responsiveness to intravitreal ranibizumab (IVR) monotherapy according to the presence of a single or multiple polyps. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - March 24, 2016 Category: Opthalmology Authors: Misa Suzuki, Norihiro Nagai, Hajime Shinoda, Atsuro Uchida, Toshihide Kurihara, Yohei Tomita, Mamoru Kamoshita, Chigusa Iyama, Kazuo Tsubota, Yoko Ozawa Tags: Original Articles Source Type: research

Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age ‐related macular degeneration: a comparative 12 Month study
Abstract PurposeTo compare outcomes in patients with treatment‐naïve neovascular age‐related macular degeneration (nAMD) receiving ranibizumab treat and extend (TE) with those receiving ranibizumab pro re nata (PRN) in a clinical setting. MethodsDuring this 12‐month retrospective, consecutive, comparative case series, patients received ranibizumab 0.5 mg according to a TE or PRN regimen. Monthly optical coherence tomography (OCT) evaluation was performed during the PRN regimen; retreatment criteria included recurrence of intra‐/subretinal fluid, or haemorrhages. During the TE regimen, initial treatment wi...
Source: Acta Ophthalmologica - March 24, 2016 Category: Opthalmology Authors: Katja Hatz, Christian Pr ünte Tags: Case Series Source Type: research

Systemic effects of intravitreal ranibizumab
Michalska-Małecka K, Kabiesz A, Kimsa MW, Strzałka-Mrozik B, Formińska-Kapuścik M, Nita M, Mazurek U (Source: Clinical Interventions in Aging)
Source: Clinical Interventions in Aging - March 23, 2016 Category: Geriatrics Source Type: research

Intravitreal Ranibizumab and Aqueous Humor Factors/Cytokines in Major and Macular Branch Retinal Vein Occlusion
Aqueous humor levels of cytokines and growth/inflammatory factors were measured in 38 patients with macular edema who had major branch retinal vein occlusion (BRVO) or macular BRVO and were treated with intravitreal ranibizumab injection (IRI). Patients with recurrence of macular edema received further IRI as needed. Aqueous humor levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1), and other cytokines/factors were measured. Compared with major BRVO, macular BRVO was associated with lower aqueous humor levels of sVEGFR-1, its ligands (VEGF and placental growth factor), and other growth/i...
Source: Ophthalmologica - March 23, 2016 Category: Opthalmology Source Type: research

[Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases].
CONCLUSION: The efficacy of aflibercept with a PRN protocol provides interesting results, with an improvement in visual acuity and central retinal thickness in all treated groups, and with fewer injections than advocated. PMID: 26995074 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - March 22, 2016 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment
Conclusion Improvement of visual acuity and reduction in macular thickness were maintained up to the 6-month follow-up. The results of electrophysiological examinations revealed that ranibizumab injections tend to stabilize bioelectrical macular function of the outer, middle and inner retinal layers, which was impossible to recognize on the basis of visual acuity and OCT. Therefore, the electrophysiological examinations should be used as an additional objective tool for the evaluation of the anti-VEGF treatment effectiveness in DME. (Source: Documenta Ophthalmologica)
Source: Documenta Ophthalmologica - March 21, 2016 Category: Opthalmology Source Type: research

Effects of commonly used intravitreal anti‐vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body
ConclusionAdministrations of high doses or repeated standard doses of intravitreal anti‐VEGF agents may affect the proliferation indexes and viabilities of CB‐MSCs and LMSCs adversely. These novel findings deserve further in vivo investigations. (Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - March 19, 2016 Category: Opthalmology Authors: Ugur Acar, Damla Erginturk Acar, Ferda Alpaslan Pinarli, Muhammed N Demir, Emrullah Beyazyildiz, Ozdemir Ozdemir, Duygu Gulmez Sevim, Meral Tiryaki, Gungor Sobaci Tags: Original Article Source Type: research

Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)
To compare study and fellow eyes in subjects with age-related macular degeneration (AMD) for 7-year outcomes arising from contrasting treatment histories and disease statuses. (Source: Ophthalmology)
Source: Ophthalmology - March 19, 2016 Category: Opthalmology Authors: Robert B. Bhisitkul, Shilpa J. Desai, David S. Boyer, SriniVas R. Sadda, Kang Zhang Source Type: research

Effects of commonly used intravitreal anti ‐vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body
ConclusionAdministrations of high doses or repeated standard doses of intravitreal anti‐VEGF agents may affect the proliferation indexes and viabilities of CB‐MSCs and LMSCs adversely. These novel findings deserve further in vivo investigations. (Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - March 19, 2016 Category: Opthalmology Authors: Ugur Acar, Damla Erginturk Acar, Ferda Alpaslan Pinarli, Muhammed N Demir, Emrullah Beyazyildiz, Ozdemir Ozdemir, Duygu Gulmez Sevim, Meral Tiryaki, Gungor Sobaci Tags: Original Article Source Type: research

Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment
Conclusions In the current study, visual acuity outcomes were generally poor. Enterococcus and Staphylococcus species were the most common organisms reported and postoperative endophthalmitis after cataract surgery was the most common clinical setting. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - March 18, 2016 Category: Opthalmology Authors: Relhan, N., Albini, T. A., Pathengay, A., Kuriyan, A. E., Miller, D., Flynn, H. W. Tags: Ophthalmologic surgical procedures, Choroid, Eye (globe), Lens and zonules Review Source Type: research

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
Abstract AIMS: To examine 12-month outcomes of eyes switching from intravitreal ranibizumab to aflibercept for neovascular age-related macular degeneration (nAMD). METHODS: Database observational study of eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that received ranibizumab for at least 12 months before switching to aflibercept and followed for at least 12 months after the switch. Visual acuity (VA) recorded at 12 months after the switch was analysed using locally weighted scatterplot smoothing curves. Lesion activity was graded according to a prospectively identified definiti...
Source: The British Journal of Ophthalmology - March 18, 2016 Category: Opthalmology Authors: Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, Guymer R, Essex RW, Morlet N, Gillies MC, Fight Retinal Blindness! Project Investigators Tags: Br J Ophthalmol Source Type: research

Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy
Conclusions: We described a case of a patient with wet-AMD refractory to anti-VEGF therapy, which clinically benefited from subcutaneous adalimumab therapy. Treatment with subcutaneous anti-TNF-α in combination with anti-VEGF therapy avoids the high cost and risks related to multiple intravitreal anti-VEGF injections with good functional and anatomic outcomes.Case Rep Ophthalmol 2016;7:154-162 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - March 17, 2016 Category: Opthalmology Source Type: research

Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE
To explore the visual acuity and anatomic outcomes over 24 months of patients with diabetic macular edema (DME) who showed a delayed anatomic response after 3 ranibizumab injections in the RIDE and RISE trials. (Source: Ophthalmology)
Source: Ophthalmology - March 16, 2016 Category: Opthalmology Authors: Dante J. Pieramici, Pin-wen Wang, Beiying Ding, Shamika Gune Source Type: research

Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment.
CONCLUSIONS Intravitreal injection of ranibizumab for the treatment of neovascular age-related macular degeneration with serous pigment epithelial detachment safely and effectively improved the patients' visual acuities and decreased their PED heights volumes. PMID: 26972376 [PubMed - in process] (Source: Medical Science Monitor)
Source: Medical Science Monitor - March 15, 2016 Category: Research Tags: Med Sci Monit Source Type: research

Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept.
CONCLUSIONS: Weight optimization and regression methods are useful options to adjust for more than one baseline characteristics. PMID: 26967930 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 13, 2016 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Novel Interaction Mechanism of a dAb-based Inhibitor [Protein Structure and Folding]
A potent VEGF inhibitor with novel antibody architecture and antigen binding mode has been developed. The molecule, hereafter referred to as VEGF dual dAb (domain antibody), was evaluated in vitro for binding to VEGF and for potency in VEGF-driven models and compared with other anti-VEGF biologics that have been used in ocular anti-angiogenic therapeutic regimes. VEGF dual dAb is more potent than bevacizumab and ranibizumab for VEGF binding, inhibition of VEGF receptor binding assays (RBAs), and VEGF-driven in vitro models of angiogenesis and displays comparable inhibition to aflibercept (Eylea). VEGF dual dAb is dimeric, ...
Source: Journal of Biological Chemistry - March 11, 2016 Category: Chemistry Authors: Walker, A., Chung, C.-W., Neu, M., Burman, M., Batuwangala, T., Jones, G., Tang, C.-M., Steward, M., Mullin, M., Tournier, N., Lewis, A., Korczynska, J., Chung, V., Catchpole, I. Tags: Molecular Biophysics Source Type: research

Five-year follow-up of bilateral choroidal neovascularization secondary to optic nerve head drusen treated with ranibizumab in a nine-year-old girl.
Authors: Benouaich X, Salmon L, Mahieu L, Soler V PMID: 26949117 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - March 8, 2016 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research